VYNE Therapeutics  logo
VYNE Therapeutics VYNE
$ 2.49 4.18%

Quarterly report 2024-Q3
added 11-07-2024

report update icon

VYNE Therapeutics Balance Sheet 2011-2024 | VYNE

Annual Balance Sheet VYNE Therapeutics

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -22.8 M -30.8 M -49.5 M -10.2 M -4.03 M -43.8 M - - - -

Long Term Debt

- - - 33.2 M - - - - - - - - -

Long Term Debt Current

115 K - 349 K 757 K - - - - - - - - -

Total Non Current Liabilities

1.41 M - - 34.8 M - 7 K 116 M 67.6 M 59.1 M - - - -

Total Current Liabilities

7.54 M 9.34 M - 21.5 M 10.7 M 9.54 M 7.82 M - - - - - -

Total Liabilities

8.95 M 9.34 M 18.4 M 56.2 M 10.7 M 9.55 M 124 M 71.5 M 59.8 M - - - -

Deferred Revenue

- - - - - - 1.8 M 1.8 M - - - - -

Retained Earnings

-691 M -663 M -640 M -566 M - -111 M -59.2 M -30.1 M -16 M - - - -

Total Assets

97.7 M 40.8 M 67 M 93.7 M 79.2 M 140 M 66.9 M 42.1 M 43.9 M - - - -

Cash and Cash Equivalents

30.6 M 30.9 M 42.2 M 57.6 M 30.8 M 49.5 M 10.2 M 4.03 M 43.8 M - - - -

Book Value

88.7 M 31.4 M 48.6 M 37.5 M 68.5 M 130 M -57 M -29.4 M -16 M - - - -

Total Shareholders Equity

88.7 M 31.2 M 48.6 M 37.5 M 17.6 M 130 M -57 M -29.4 M -16 M - - - -

All numbers in USD currency

Quarterly Balance Sheet VYNE Therapeutics

2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 99 K - - - - - - - - - - 33.3 M 33.2 M 33.2 M 33.2 M 33.2 M 32.7 M 32.7 M 32.7 M 32.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- 25 K 1.41 M - - - - - - - - - - - 34.5 M 35 M 35.1 M 34.4 M 34.3 M 34.3 M 34.3 M 34.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

12.7 M 11.8 M 8.95 M 7.76 M 7.69 M 8.83 M 9.34 M 6.84 M 6.84 M 8.59 M 18.4 M 22.4 M 59.1 M 56.3 M 56.2 M 56.2 M 56.2 M 56.2 M 63.6 M 63.6 M 63.6 M 63.6 M 9.55 M 9.55 M 9.55 M 9.55 M 14.6 M 14.6 M 14.6 M 14.6 M 12.5 M - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - 1.8 M 1.8 M 1.8 M 1.8 M 1.8 M 1.8 M - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-719 M -707 M -691 M -685 M -679 M -669 M -663 M -653 M -643 M -635 M -640 M -628 M -607 M -587 M -566 M -566 M -566 M -566 M -311 M -311 M -311 M -311 M -111 M -111 M -111 M -111 M -59.2 M -59.2 M -59.2 M -59.2 M -30.1 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

76.2 M 86.6 M 97.7 M 19.3 M 25 M 35.3 M 40.8 M 46.9 M 55.2 M 64.3 M 67 M 81.3 M 134 M 149 M 93.7 M 93.7 M 93.7 M 93.7 M 81.2 M 81.2 M 81.2 M 81.2 M 140 M 140 M 140 M 140 M 66.9 M 66.9 M 66.9 M 66.9 M 42.1 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

16.3 M 29.6 M 30.6 M 15.4 M 20.6 M 30.2 M 30.9 M 35.5 M 42.8 M 50.5 M 42.2 M 52.3 M 103 M 119 M 57.6 M 57.6 M 57.6 M 57.6 M 43.8 M 43.8 M 43.8 M 43.8 M 27.9 M 49.5 M 49.5 M 49.5 M 10.2 M 10.2 M 10.2 M 10.2 M 4.03 M - - - 43.8 M - - - 273 K - - - - - - - - - - - - - - -

Book Value

63.5 M 74.9 M 88.7 M 11.5 M 17.3 M 26.4 M 31.4 M 40.1 M 48.4 M 55.7 M 48.6 M 58.9 M 74.9 M 92.9 M 37.5 M 37.5 M 37.5 M 37.5 M 17.6 M 17.6 M 17.6 M 17.6 M 130 M 130 M 130 M 130 M 52.3 M 52.3 M 52.3 M 52.3 M 29.6 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

63.5 M 74.9 M 88.7 M 11.5 M 17.3 M 26.4 M 31.2 M 40.1 M 48.4 M 55.7 M 48.6 M 58.9 M 74.9 M 92.9 M 37.5 M 37.5 M 37.5 M 37.5 M 17.6 M 17.6 M 17.6 M 17.6 M 92.2 M 130 M 130 M 130 M 68.6 M -57 M -57 M -57 M -29.4 M - - - -16 M - - - -11.4 M - - - - - - - - - - - - - - -

All numbers in USD currency